Skip to main content
. 2021 Mar 15;14(6):101059. doi: 10.1016/j.tranon.2021.101059

Fig. 3.

Fig 3

IRF2 and β-catenin are upregulated in lenvatinib treated HCC cells. A. Immunoblotting of IRF2 and β-catenin in Huh7 cells treated with 0, 2.5, 7.5 µM of lenvatinib for 48 h (left panel). And immunoblotting of IRF2 and β-catenin in Huh7 cells treated with 0, 7.5 µM of lenvatinib for 48 h or 72 h (right panel); B. mRNA levels of IRF2 and β-catenin in Huh7 cells treated with 0, 2.5, 7.5 µM of lenvatinib for 48 h (left panel). And mRNA levels of IRF2 and β-catenin in Huh7 cells treated with 0, 7.5 µM of lenvatinib for 48 h or 72 h (right panel). Student's t-test; C. Immunoblotting of IRF2 and β-catenin in HepG2 cells treated with 0, 2.5, 7.5 µM of lenvatinib for 48 h (left panel). And immunoblotting of IRF2 and β-catenin in HepG2 cells treated with 0, 7.5 µM of lenvatinib for 48 h or 72 h (right panel); D. mRNA levels of IRF2 and β-catenin in HepG2 cells treated with 0, 2.5, 7.5 µM of lenvatinib for 48 h (left panel). And mRNA levels of IRF2 and β-catenin in HepG2 cells treated with 0, 7.5 µM of lenvatinib for 48 h or 72 h (right panel). Student's t-test; E. Immunofluorescence staining of IRF2 (red), β-catenin (green) and DAPI (blue) in HepG2 and Huh7 cells treated with 0 and 7.5 µM of lenvatinib for 48 h.